Characteristic All (n=103) I-IIA (n=62) IIB-IIIC (n=41) P-value
Age (years) Age (years) 0.429
Median 48 47 48
IQR 41-54 40-53 43-55
Family history of malignancy, n (%) Family history of malignancy, n (%) 0.737
None 89 (86.4) 53 (85.5) 36 (87.8)
Yes 14 (13.6) 9 (14.5) 5 (12.2)
Histology, n (%) Histology, n (%) 0.858
Pure 82 (79.6) 49 (79.0) 33 (80.5)
Mixed 21 (20.4) 13 (21.0) 8 (19.5)
Tumor size, n (%) <0.001
<4cm 62 (60.2) 46 (74.2) 16 (39.0)
≥4cm 41 (39.8) 16 (25.8) 25 (61.0)
Lymph node <0.001
Negative 71 (68.9) 62 (100) 9 (22.0)
Positive 32 (31.1) 0 (0) 32 (78.0)
Chemotherapy regimen, n (%) Chemotherapy regimen, n (%) 0.341
EP 66 (64.1) 42 (67.7) 24 (58.5)
non-EP 37 (35.9) 20 (32.3) 17 (41.5)
Chemotherapy courses, n (%) Chemotherapy courses, n (%) 0.313
1-4 49 (47.6) 32 (51.6) 17 (41.5)
≥5 54 (52.4) 30 (48.4) 24 (58.5)
Chemotherapy sequencing, n (%) Chemotherapy sequencing, n (%) 0.358
IC 4 (3.9) 3 (4.8) 1 (2.4)
ACT 62 (60.2) 40 (64.5) 22 (53.7)
IC+ACT 37 (35.9) 19 (30.6) 18 (43.9)
Treatment modality, n (%) Treatment modality, n (%) 0.004
S+CT 39 (37.9) 31 (50.0) 8 (19.5)
S+RT+CT 52 (50.5) 27 (43.5) 25 (61.0)
RT+CT 12 (11.7) 4 (6.5) 8 (19.5)